Exeltis USA, In Patent-Cliff Exposure & CMS Drug Spending Portfolio

Exeltis USA, In (US): 10 reconciled FDA prescription therapies, $26.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies10
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$26.4M
2024 Medicare Part D Spend$61K
2024 Medicaid Spend$26.4M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel